Artelo Biosciences Achieves Positive Preclinical Data for ART26.12 in Spinal Cord Injury Neuropathic Pain

Formulation and CMC teams tracking non-opioid analgesic pipelines should note that Artelo Biosciences has added a spinal cord injury model to the preclinical evidence base for ART26.12, its selective FABP5 inhibitor currently in Phase 1 development, broadening the candidate's potential indication scope ahead of human efficacy studies.

The nonclinical study, conducted at Stony Brook University and presented at the International Cannabinoid Research Society 2026 Annual Symposium in Dijon, France, evaluated ART26.12 in a validated mouse model of spinal cord injury-induced neuropathic pain. Investigators reported that selective FABP5 inhibition reduced mechanical hypersensitivity, decreased spontaneous pain-related behaviors, suppressed nociceptor hyperexcitability, and improved pain outcomes following oral administration. The oral route finding carries direct relevance for formulation strategy as the program advances toward later-phase studies.

These results extend ART26.12's preclinical profile beyond previously reported painful neuropathy indications. Up to 60% of individuals living with spinal cord injuries experience neuropathic pain that is frequently resistant to available therapies, a population with limited pharmacological options and a high unmet need that regulators and payers have historically scrutinized for meaningful differentiation.

For drug development and regulatory affairs leads, the mechanistic angle warrants attention. ART26.12 targets lipid-signaling pathways through peripheral FABP5 inhibition rather than central opioid receptors, positioning it outside the scheduling and abuse-liability framework that governs current standard-of-care analgesics. That distinction will shape the IND and eventual NDA safety narrative, particularly around non-clinical pharmacology package requirements under 21 CFR Part 312 and ICH S7A/S7B guidance.

Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, delivered the presentation and noted that FABP5 inhibition suppresses nociceptor hypersensitivity and spontaneous pain behaviors following spinal cord injury, supporting continued exploration as a novel analgesic strategy. Artelo CEO Gregory Gorgas indicated the company intends to advance ART26.12 in human studies, citing the breadth of activity observed across multiple disease models.

The Phase 1 program's progression will determine how quickly CMC teams must resolve the formulation questions, oral bioavailability, polymorphic form selection, and stability under ICH Q1A conditions, that preclinical oral-dosing results leave open.

Source: Artelo Biosciences, Inc. via GlobeNewswire, July 1, 2026.